RENAL DENERVATION IN THE TREATMENT OF RESISTANT HYPERTENSION: RESULTS OF A ONE-YEAR OBSERVATIONAL STUDY
https://doi.org/10.20996/1819-6446-2015-11-3-304-308
Abstract
Aim. To study the effect of renal denervation on blood pressure (BP), myocardium function and vegetative status in patients with resistant hypertension (HT).
Material and methods. Patients with a provisional resistant HT diagnosis (n=62; 41.3% male) were included into the study. 17 patients were selected for renal denervation after correction of previous antihypertensive therapy and examination to exclude symptomatic HT. Two patients refused the procedure, 1 patient hadn’t undergone renal denervation due to anatomical features (renal artery diameter <4 mm). Renal denervation was performed in 14 patients. Office and average daily BP, kidney function, the severity of left ventricular hypertrophy and heart rate variability were assessed initially and after the intervention.
Results. Office systolic BP (SBP) decreased from 165 to 150 mm Hg (p=0.016), diastolic BP (DBP) - from 110 to 95 mm Hg (p=0.019) 12 months after the renal denervation. Average daily SBP decreased from 148 to 137 mm Hg (p=0.092), average daily DBP - from 90 to 80 mm Hg (p=0.401). Plasma creatinine level and glomerular filtration rate remained within the reference range at a baseline and in 12 months. Left ventricular hypertrophy measured by echocardiography has not changed significantly. No significant heart rate variability dynamics has been found.
Conclusion. Renal denervation is a promising treatment for resistant HT. The effect of renal denervation on the dynamics of left ventricular hypertrophy and heart rate variability requires updating.
About the Authors
V. A. SulimovRussian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
A. V. Rodionov
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
A. A. Svetankova
Russian Federation
Trubetskaya ul. 8-2, Moscow, 119991 Russia
References
1. Mancia G., Fagard R., Narkiewicz K., et al.; ESH-ESC Task Force on the Management of Arterial Hypertension. 2013 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. Eur Heart J 2013 Jul;34(28):2159-219.
2. Konradi S.A. Key achievements in the combined antihypertensive therapy in recent years. Arterial'naya Gipertenziya 2012; 18 (6): 1-5. Russian (Конради А.О. Ключевые достижения в комбинированной антигипертензивной терапии последних лет. Артериальная Гипертензия 2012; 18(6):1-5).
3. Schlaich M., Sobotka P. Krum H. et al. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009; 54:1195-201.
4. Schmieder R.E., Redon J., Grassi G. et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012; 30(5):837-41.
5. Warchol-Celinska E., Prejbisz A., Florczak E. et al. Renal denervation – current evidence and perspectives. Postepy Kardiol Interwencyjnej 2013; 9(4):362-8.
6. Esler MD, Krum H, Schlaich M et al. Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension. One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial. Circulation 2012; 126:2979-82.
7. Kandzari DE, Bhatt DL, Brar S et al. Predictors of blood pressure response in the Symplcity HTN-3 trial. Eur Heart J 2015; 36:219-27.
8. Warchol-Celinska E., Januszewicz A., Prejbisz A. et al. Renal denervation after the simplicity HTN-3 trial. Postepy Kardiol Interwencyjnej 2014; 10(2):75-7.
Review
For citations:
Sulimov V.A., Rodionov A.V., Svetankova A.A. RENAL DENERVATION IN THE TREATMENT OF RESISTANT HYPERTENSION: RESULTS OF A ONE-YEAR OBSERVATIONAL STUDY. Rational Pharmacotherapy in Cardiology. 2015;11(3):304-308. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-3-304-308